Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07165197
Recruiting Not applicable

Visual Performance of Clareon Vivity and PureSee IOL

NCT07165197 · tracked via the Priya Life Science Spain tracker
Sponsor
OMIQ Research
Phase
Not applicable
Started
2025-06-27
Last updated
2025-09-10

Condition(s) studied

Cataract

Investigational drug(s) / intervention(s)

Phacoemulsification with implantation of an extended depth of focus intraocular lens

Phacoemulsification with implantation of an extended depth of focus intraocular lens: Comparison of two different Extended depth of focus intraocular lenses

Study summary

This is study to determine the visual performance of patients with age-related cataracts implanted in both eyes with either of two extended depth of focus intraocular lenses, the Clareon Vivity (Alcon Healthcare) or the PureSee (Johnson \& Johnson)

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients of any sex and race aged 50 years or older * Patients undergoing bilateral age-related cataract surgery with a lens opacity grade 3 or higher in the LOCS III grading scale * Willing to receive implantation of an EDOF IOL * Willing to sign the informed consent and attend the study visits Exclusion Criteria: * Requirement of a spherical or toric power of the IOL to achieve emmetropia beyond the available range of either of the two lenses * The number of patients included with low astigmatism that require an equivalent to a T2 toric IOL will be capped to 10 patients/group * Irregular astigmatism * Contact lens wear in the previous 3 weeks before biometry * Moderate or severe ocular surface, corneal, macular or optic nerve disease that in opinion of the investigator precludes the desired functional results * History of previous refractive, cornea, retina or glaucoma surgery * Eyes with a clear lens demanding a refractive lens exchange * Amblyopia in any eye * Significant previous ocular trauma * Pregnancy * A systemic condition that, in the opinion of the investigator, precludes the reliable assessments required in the study (i.e., dementia) or participation in the study (i.e., severe mobility problems).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
OMIQ Research Sant Cugat del Vallès Barcelona Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07165197 on ClinicalTrials.gov ↗ ← All trials in Spain